CBD shows preclinical promise for treating cocaine and methamphetamine addiction through multiple mechanisms

A review of preclinical evidence found CBD reversed cocaine toxicity, reduced motivation to self-administer stimulants, enhanced extinction of drug memories, and prevented relapse in animal models, with several plausible mechanisms identified.

Calpe-López, Claudia et al.·Molecules (Basel·2019·Preliminary EvidenceReview
RTHC-01970ReviewPreliminary Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

CBD reversed cocaine-induced toxicity and seizures, blocked amphetamine behavioral sensitization, reduced cocaine and methamphetamine self-administration, promoted extinction of drug-place associations, and prevented stress- and drug-induced reinstatement. Observational human studies suggest CBD may reduce crack-cocaine withdrawal, craving, impulsivity, and paranoia.

Key Numbers

CBD prevented cocaine seizures and toxicity. Reduced self-administration of cocaine and METH. Enhanced extinction and impaired reconsolidation of cocaine conditioned place preference. Prevented priming-induced reinstatement of METH seeking. Observational data: reduced craving, impulsivity, paranoia.

How They Did This

Review of preclinical and limited human research on CBD effects on cocaine and methamphetamine use disorders, plus analysis of potential mechanisms including neuroadaptation prevention, drug memory erasure, cognitive restoration, and mental health comorbidity treatment.

Why This Research Matters

There are currently no approved medications for cocaine or methamphetamine addiction. If CBD can reduce relapse and craving through the multiple mechanisms identified, it could fill a critical gap in addiction treatment.

The Bigger Picture

The breadth of CBD effects on stimulant addiction, from toxicity protection to relapse prevention, suggests it may act on fundamental addiction processes rather than a single pathway. This multi-target profile could be uniquely suited to the complexity of addiction.

What This Study Doesn't Tell Us

Most evidence is preclinical. Observational human data is preliminary. CBD doses used in animal studies may not translate to humans. The specific mechanisms remain hypothetical. No completed randomized controlled trials in humans.

Questions This Raises

  • ?Will CBD show efficacy in randomized human trials for stimulant addiction?
  • ?What is the optimal dose and duration of CBD treatment?
  • ?Could CBD be combined with behavioral therapies for additive effects?

Trust & Context

Key Stat:
No approved stimulant addiction meds
Evidence Grade:
Rated preliminary because the evidence is predominantly preclinical, with only observational human data available.
Study Age:
Published in 2019. Clinical trials of CBD for stimulant addiction may have progressed since.
Original Title:
Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms.
Published In:
Molecules (Basel, Switzerland), 24(14) (2019)
Database ID:
RTHC-01970

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Could CBD help treat cocaine or meth addiction?

Animal studies show promising results including reduced drug-seeking and relapse prevention. Limited human observations suggest reduced craving and withdrawal. But no randomized controlled trials have been completed yet.

How might CBD work for stimulant addiction?

Multiple mechanisms are proposed: preventing drug-induced brain changes, erasing drug-associated memories, restoring cognitive function, and treating coexisting mental health conditions that drive substance use.

Read More on RethinkTHC

Cite This Study

RTHC-01970·https://rethinkthc.com/research/RTHC-01970

APA

Calpe-López, Claudia; García-Pardo, M Pilar; Aguilar, Maria A. (2019). Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms.. Molecules (Basel, Switzerland), 24(14). https://doi.org/10.3390/molecules24142583

MLA

Calpe-López, Claudia, et al. "Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms.." Molecules (Basel, 2019. https://doi.org/10.3390/molecules24142583

RethinkTHC

RethinkTHC Research Database. "Cannabidiol Treatment Might Promote Resilience to Cocaine an..." RTHC-01970. Retrieved from https://rethinkthc.com/research/calpe-lopez-2019-cannabidiol-treatment-might-promote

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.